ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bofanglutide

Also written as “GZR18”, “GZR18 injection” and “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive, led by 2 companies.

Drug pageBofanglutide: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 5, 202425 company-led studies, 9 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gan & Lee Pharmaceuticalsits history only237 open or runningphase 3since Dec 5, 2024Feb 25, 2022Jun 30, 2027phase 3 · NCT07150975
Carnot Laboratories22 open or runningphase 3since May 24, 2026May 24, 2026Oct 2027phase 3 · NCT07628985

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Carnot Laboratories only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 29, 2024Named bofanglutideINNProposed as its International Nonproprietary Name in WHO's List 130
  2. May 24, 2026First studies: 2 phase 3 studiesFirst studyNCT07628985, NCT07622810

Ahead

  1. Oct 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07628985
  2. Dec 2027Primary completion: phase 3 study in ObesityNCT07622810

TargetBeta

GLP1R →read by rule
“Bofanglutide (GZR18) is a long-acting GLP-1 receptor agonist administered by subcutaneous injection every 2 weeks.”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 2 Carnot Laboratories leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07628985Diabetes Mellitus, Type 2 · Mexico3Not yet recruitingOct 2027374
NCT07622810Obesity · Mexico3Not yet recruitingDec 2027352

How it is read

Names in the registry

  • “GZR18”, 13 entries
  • “GZR18 injection”, 8 entries
  • “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”, 1 entry
  • “GZR18 injection A”, 1 entry
  • “GZR18 injection B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.